GE HealthCare to benefit from updated NCCN breast cancer guidelines
MicroStockHub/iStock via Getty Images

GE HealthCare (NASDAQ:GEHC) highlighted its Cerianna FES PET imaging agent on Wednesday, noting that NCCN Guidelines now recommend the use of FES PET imaging in estrogen receptor (ER) positive breast cancer.
Indicated as an adjunct to biopsy to detect ER+ breast cancer lesions, Cerianna (fluoroestradiol F18) injection is the only FDA-approved FES PET imaging agent available in the U.S.

NCCN, a not-for-profit organization comprising 33 leading U.S. cancer centers, issues guidelines that are considered the gold standard for clinical direction and policy in cancer management.
âWe are delighted to see the inclusion of Cerianna PET in the NCCN breast oncology guidelines, for potential use when oncologists are evaluating metastatic breast cancer patients,â the Chief Medical Officer of GEHCâs Pharmaceutical Diagnostics segment said.

More on GE HealthCare

GE HealthCare gets new finance chief
GE HealthCare neutral at UBS citing valuation
GE HealthCare Technologies Is A Healthy Opportunity